NCT04157049 is a clinical trial in Alpha 1-Antitrypsin Deficiency, sponsored by Alpha-1 Foundation.

Who is sponsoring NCT04157049?

NCT04157049 is sponsored by Alpha-1 Foundation.

What condition does NCT04157049 study?

NCT04157049 studies Alpha 1-Antitrypsin Deficiency.

Is NCT04157049 still recruiting?

NCT04157049 is currently recruiting now. Last updated 30 January 2024.

Last reviewed 2024-01-30 · How we verify

NCT04157049

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alpha-1 Research Registry

Recruiting now Last updated 30 January 2024

What this trial tests

trial in Alpha 1-Antitrypsin Deficiency in 4,000 participants. Currently enrolling.

Timeline

20 June 2019

Primary endpoint
20 June 2029

20 June 2029

Quick facts

Lead sponsor	Alpha-1 Foundation
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	4,000
Start date	20 June 2019
Primary completion	20 June 2029
Estimated completion	20 June 2029
Sites	1 location across United States

Conditions studied

Alpha 1-Antitrypsin Deficiency — all drugs for Alpha 1-Antitrypsin Deficiency →

Sponsor

Alpha-1 Foundation

Who can join

Eligibility, any sex, with Alpha 1-Antitrypsin Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Alpha-1 Research Registry is a confidential database made up of individuals diagnosed with Alpha-1 Antitrypsin Deficiency (Alpha-1) and individuals identified as Alpha-1 carriers. The Registry was established to facilitate research initiatives and promote the development of improved treatments and a cure for Alpha-1.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Rationale and Design of the Alpha-1 Biomarkers Consortium Study.
Goldklang MP, Pirozzi C, Barjaktarevic I, Bhatt SP, et al · · 2025 · PMID 40273316 · DOI 10.15326/jcopdf.2025.0603

Verify or expand the search:

Other recruiting trials for Alpha 1-Antitrypsin Deficiency

Currently open trials in the same condition.

NCT06996756 — Gene Therapy for Alpha 1- Antitrypsin Deficiency · Phase 1 · recruiting
NCT05897424 — Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04157049 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alpha-1 Foundation
Last refreshed: 30 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04157049.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing